Allergan Reports Third Quarter 2012 Operating Results
Thanks for reprinting the obvious. What needs to be discussed is Lapband and the rest of the Medical division. When is Pyott spinning off the implant side of the business? Does anyone think that implants will continue the 15% growth rate he is expecting???
Okay, the typical selloff following earnings with so many quality stocks. I am looking to buy again after we get some more facts on the table with the disaster aftermath and the elections stuff. I was fortunate to pull off some shares off on the last rally, and now, it is getting ripe again for money to flow back into it. I like $86-87 if I can get a chance.
You see everyone, we don't get those chances for dips. I glad my core position is doing really well and this looks like it wants to run a bit for now. I will take some off. So, on pull backs, it is a buy.
I actually agree with management's call on the LapBand. It is a very profitable business but it is not fitting into the AGN's long term strategy. It's a great product, and a good and profitable business but it is perhaps AGN's only product that is most sensitive to, and most affected by the economic cycle.
The implant side of the business is extremely healthy and should be kept. This implant business is an expanding -- global -- business, and AGN is a major player in this market. Why would you abandon a lucrative and expanding market? AGN is position to become the global leader -- if it isn't already -- especially with the recent development with the primo positioning in the Japan implant market.
This is precisely the kind of product and position that AGN loves, and will make mammary implants a key part of the aesthetic mix for the long haul.
Dude, you need to do some more homework, or perhaps you were not actively listening to yesterday's conf. call.